Notice of Special Interest: Synthetic Biology for Biomedical Applications (NOT-EB-23-002)
Support for R01 and R21 projects across multiple NIH institutes to develop and apply synthetic biology tools—engineered gene circuits, cells, tissues, biosensors, computational frameworks, etc.—for basic and translational research in cancer, heart/lung/blood diseases, aging, infectious/immune disorders, pediatric/developmental biology, complementary health, and fundamental biomedical processes.
Eligibility Criteria
-
Eligible applicants are those invited by the corresponding parent FOAs (see “Funding Details” below): U.S. and foreign Higher-Education Institutions, non-profits (with or without 501(c)(3)), for-profits (including SBIR/STTR), state/local governments, tribal entities, and faith- or community-based organizations.
-
PD(s)/PI(s) must meet parent-announcement requirements (R01/R21 mechanisms, clinical trial status as specified by each FOA).
-
Multi-PD/PI applications are allowed if permitted by the parent FOA.
-
Applications proposing only basic mechanistic clinical protocols not aligned with the parent FOA’s clinical-trial requirement are non-responsive.
Deadline
-
Expiration Date: May 17, 2026
-
Thereafter, submit at standard NIH receipt dates (e.g., June 5 and October 5 each year) until May 17, 2026.
Application Instructions
-
Choose the parent FOA that matches your clinical-trial design and institute of interest.
-
Enter “NOT-EB-23-002” in box 4B of the SF424 (R&R) Cover.
-
Follow all instructions in the selected FOA (page limits, budget caps, appendix rules, human/animal protocols).
-
Discuss project fit with the relevant Program Officer well before the due date.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023